Literature DB >> 18781337

Medical management of children with primary hypertension by pediatric subspecialists.

Esther Y Yoon1, Matthew M Davis, Albert Rocchini, David Kershaw, Gary L Freed.   

Abstract

Our aim was to characterize medical management of children with primary hypertension (HTN) by pediatric subspecialists. We performed a medical-record review of children < or = 18 years with primary HTN seen at pediatric cardiology or pediatric nephrology clinics at an academic center. Main outcomes were whether treatment decision was in agreement with national guidelines, whether an antihypertensive medication was prescribed, and medication choice. One hundred and eighty children had > or = 1 visit to a pediatric cardiology or nephrology clinic. The majority (83%) of children were pharmacologically managed according to national guidelines. However, only 1/3 children with stage 2 HTN received appropriate antihypertensive therapy from either subspecialty. Only 26 children were prescribed an antihypertensive drug. Children evaluated by pediatric nephrologists were fourfold more likely to receive an antihypertensive than children seen by pediatric cardiologists (29% vs. 7%; p < 0.001). However, all antihypertensive prescriptions were prescribed according to guidelines by both subspecialties. Medical management of children with primary HTN by pediatric cardiologists and pediatric nephrologists is largely consistent with guidelines. However, initiation of appropriate antihypertensive drugs for children with highest severity of HTN is equally poor for both subspecialties. Future studies should explore the factors underlying physicians' reluctance to initiate recommended chronic pharmacologic therapy in children and its associated outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781337     DOI: 10.1007/s00467-008-0970-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  29 in total

Review 1.  Why don't physicians follow clinical practice guidelines? A framework for improvement.

Authors:  M D Cabana; C S Rand; N R Powe; A W Wu; M H Wilson; P A Abboud; H R Rubin
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.

Authors: 
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

3.  The impact of allergy and pulmonary specialist care on emergency asthma utilization in a large managed care organization.

Authors:  Sara Erickson; Irina Tolstykh; Joe V Selby; Guillermo Mendoza; Carlos Iribarren; Mark D Eisner
Journal:  Health Serv Res       Date:  2005-10       Impact factor: 3.402

4.  Direct-to-consumer advertising of COX-2 inhibitors: effect on appropriateness of prescribing.

Authors:  Michele M Spence; Stephanie S Teleki; T Craig Cheetham; Stuart O Schweitzer; Mirta Millares
Journal:  Med Care Res Rev       Date:  2005-10       Impact factor: 3.929

5.  Barriers pediatricians face when using asthma practice guidelines.

Authors:  M D Cabana; B E Ebel; L Cooper-Patrick; N R Powe; H R Rubin; C S Rand
Journal:  Arch Pediatr Adolesc Med       Date:  2000-07

6.  Self-reported physician practices for children with asthma: are national guidelines followed?

Authors:  J A Finkelstein; P Lozano; R Shulruff; T S Inui; S B Soumerai; M Ng; K B Weiss
Journal:  Pediatrics       Date:  2000-10       Impact factor: 7.124

7.  Screening for hypertension in a high school population.

Authors:  D S Silverberg; C V Nostrand; B Juchli; E S Smith; E V Dorsser
Journal:  Can Med Assoc J       Date:  1975-07-26       Impact factor: 8.262

8.  Direct observation of requests for clinical services in office practice: what do patients want and do they get it?

Authors:  Richard L Kravitz; Robert A Bell; Rahman Azari; Steven Kelly-Reif; Edward Krupat; David H Thom
Journal:  Arch Intern Med       Date:  2003-07-28

Review 9.  Lipid screening and cardiovascular health in childhood.

Authors:  Stephen R Daniels; Frank R Greer
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

10.  Prevalence of hypertension and pre-hypertension among adolescents.

Authors:  Karen L McNiece; Timothy S Poffenbarger; Jennifer L Turner; Kathy D Franco; Jonathan M Sorof; Ronald J Portman
Journal:  J Pediatr       Date:  2007-06       Impact factor: 4.406

View more
  7 in total

1.  Antihypertensive prescribing patterns for adolescents with primary hypertension.

Authors:  Esther Y Yoon; Lisa Cohn; Albert Rocchini; David Kershaw; Gary Freed; Frank Ascione; Sarah Clark
Journal:  Pediatrics       Date:  2011-12-05       Impact factor: 7.124

2.  Underlying Rationale and Approach to Treat Hypertension in Adolescents by Physicians of Different Specialty.

Authors:  Esther Y Yoon; Julie S Weber; Brigitte McCool; Albert Rocchini; David Kershaw; Gary Freed; Frank Ascione; Sarah Clark
Journal:  Ann Pediatr Child Health       Date:  2013

3.  Treating Hypertension in Children With n-of-1 Trials.

Authors:  Joyce P Samuel; Jon E Tyson; Charles Green; Cynthia S Bell; Claudia Pedroza; Don Molony; Joshua Samuels
Journal:  Pediatrics       Date:  2019-03-06       Impact factor: 7.124

Review 4.  Hypertension in children and adolescents: an approach to management of complex hyper-tension in pediatric patients.

Authors:  Kevin Meyers; Bonita Falkner
Journal:  Curr Hypertens Rep       Date:  2009-10       Impact factor: 5.369

Review 5.  Assessment and management of hypertension in children and adolescents.

Authors:  Brian W McCrindle
Journal:  Nat Rev Cardiol       Date:  2010-01-12       Impact factor: 32.419

6.  High blood pressure in children and adolescents: to treat or not to treat is not the question.

Authors:  George A Mensah
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-12       Impact factor: 3.738

7.  Comparative effectiveness of antihypertensive treatment for older children with primary hypertension: study protocol for a series of n-of-1 randomized trials.

Authors:  Joyce P Samuel; Joshua A Samuels; Lauren E Brooks; Cynthia S Bell; Claudia Pedroza; Donald A Molony; Jon E Tyson
Journal:  Trials       Date:  2016-01-08       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.